New Gene Therapy May Prove Useful Against Cancer Patients' Fungal Infections
the Cancer Therapy Advisor take:
The Sleeping Beauty gene transfer system “awakens” transposon, which are DNA sequences that researchers find useful for altering DNA inside human cells. Sleeping Beauty exploits the transposon so that it can relocate genetic material with a “cut and paste” approach.
According to a study published in Proceedings of the National Academy of Sciences, researchers fought infections by invasive Aspergillus fungus by modifying T cells with the Sleeping Beauty gene transfer system. Research leader Laurence Cooper, MD, PhD, and researchers at The University of Texas MD Anderson Cancer Center used Sleeping Beauty to make T cells express chimeric antigen receptors (CARs), which caused the T cells to target sugar molecules in Aspergillus cell walls. This approach may prove useful for immunosuppressed patients, such as patients with hematopoietic stem cell transplants, which treat blood or bone marrow cancers.
Dimitrios Kontoyiannis, MD, ScD, said although antifungal therapies are available, the drugs’ effectiveness is compromised due to the patient’s weakened immune system from hematopoietic stem cell transplants as well as emerging resistance to antifungals. Cooper said that his research team studied their new gene therapy against fungus due to CARs’ successful treatment of patients with B-cell malignancies.
Redirecting T-cell specificity opens up the potential for more investigations of its effects on other pathogens and malignancies.
New Gene Therapy May Prove Useful Against Cancer Patients’ Fungal Infections
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer